Nootropic / neuroprotective peptide (ACTH(4-10) analog)
A synthetic modified ACTH fragment used as a cognitive-enhancing and neuroprotective agent (nasal spray or injection).
| Class / type | Nootropic / neuroprotective peptide (ACTH(4-10) analog) |
|---|---|
| Category | Cognitive & Nootropic |
| Status (Jul 2026) | Research use only |
Semax is a synthetic modified fragment of the hormone ACTH, developed and marketed in Russia as a neuroprotective and cognitive-enhancing drug. Importantly, the modification strips out ACTH's hormonal (adrenal) activity, leaving the brain effects.
In the US it isn't approved and is sold as a research chemical, typically used as a nasal spray or injection.
Semax rapidly increases BDNF (brain-derived neurotrophic factor) and its receptor in the hippocampus, and modulates dopamine and serotonin signaling. BDNF supports neuroplasticity - the brain's ability to form and strengthen connections.
In Russia it's used clinically for ischemic stroke, transient ischemic attack and cognitive disorders, backed by domestic clinical use and strong preclinical BDNF data. Rigorous Western placebo-controlled trials are limited, so much of the evidence is Russian and not FDA-reviewed.
Users report improved focus, mental clarity, processing speed and mood, often with fast onset and without stimulant jitters or a crash.
Strong neuroplasticity/BDNF rationale and a track record of clinical use abroad.
Limited high-quality Western trials; most human data are Russian. Reported effects are usually mild - nasal irritation, headache, occasional overstimulation or irritability.
Long-term safety data are sparse and gray-market purity is a concern.
Marketed as a drug in Russia. In the US it's research-use-only. In July 2026 an FDA advisory panel voted to recommend it for compounding, though that vote is advisory and not yet final. Commonly used intranasally.
A 'clean', non-stimulant focus and clarity boost without jitters or crash.
Approved as a drug in Russia; NOT FDA-approved in the US. On Jul 24, 2026 the FDA's PCAC voted to recommend it for 503A compounding (advisory and non-binding); no final rule yet. Research-use-only. The next step is formal FDA rulemaking with a public comment period, and the FDA may allow interim enforcement discretion in the meantime. Verify.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.